fluoxetine has been researched along with Acute Disease in 66 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with ischaemic stroke and moderate to severe motor deficit, the early prescription of fluoxetine with physiotherapy enhanced motor recovery after 3 months." | 9.15 | Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. ( Albucher, JF; Arnaud, C; Bejot, Y; Berard, E; Chollet, F; Deltour, S; Guillon, B; Jaillard, A; Lamy, C; Loubinoux, I; Marque, P; Moulin, T; Niclot, P; Pariente, J; Tardy, J; Thalamas, C, 2011) |
| "Fluoxetine use was not associated with an increased risk of acute pancreatitis compared with citalopram or other SSRIs." | 8.12 | Investigation of the potential association between the use of fluoxetine and occurrence of acute pancreatitis: a Danish register-based cohort study. ( Aakjær, M; Andersen, M; Dalhoff, KP; De Bruin, ML; Kristiansen, SB; Pape, K; Sessa, M, 2022) |
| "Myocarditis is an increasingly recognized complication associated with the use of clozapine." | 7.74 | Acute myocarditis associated with clozapine. ( Howpage, P; Varambally, S, 2007) |
| " We present the case of a young man who developed an acute akathisia and dystonia after inadvertent overdose of olanzapine (Zyprexa) in the setting of a recent discontinuation of fluoxetine." | 7.73 | Acute olanzapine-induced akathisia and dystonia in a patient discontinued from fluoxetine. ( Dufel, S; Paige, T; Vena, J, 2006) |
| "We report a case of a 32-year-old woman who developed paroxysmal episodes of right hemidystonia 2 days after taking fluoxetine." | 7.71 | Acute paroxysmal dystonia induced by fluoxetine. ( Callejo, JM; Domínguez-Morán, JA; Fernández-Ruiz, LC; Martínez-Castrillo, JC, 2001) |
| " This was combined with two different doses of fluoxetine (10 and 20 mg/kg)." | 5.37 | Evaluation of antidepressant activity of ropinirole coadministered with fluoxetine in acute and chronic behavioral models of depression in rats. ( Ghorpade, S; Manjrekar, N; Sonawane, D; Tripathi, R, 2011) |
| "In patients with ischaemic stroke and moderate to severe motor deficit, the early prescription of fluoxetine with physiotherapy enhanced motor recovery after 3 months." | 5.15 | Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. ( Albucher, JF; Arnaud, C; Bejot, Y; Berard, E; Chollet, F; Deltour, S; Guillon, B; Jaillard, A; Lamy, C; Loubinoux, I; Marque, P; Moulin, T; Niclot, P; Pariente, J; Tardy, J; Thalamas, C, 2011) |
| "The objective was to present naturalistic 1-year follow-up information of 96 child and adolescent outpatients with major depressive disorder who had been randomized in an 8-week double-blind, placebo-controlled trial of fluoxetine." | 5.08 | Fluoxetine in child and adolescent depression: acute and maintenance treatment. ( Carmody, T; Emslie, GJ; Kowatch, RA; Mayes, TL; Rush, AJ; Weinberg, WA, 1998) |
| "The 2 older FDA-approved treatments for bipolar depression, olanzapine-fluoxetine combination (OFC) and quetiapine (QTP) monotherapy, were efficacious (response NNT=4 for OFC, NNT=6 for QTP), but similarly likely to yield harms (OFC weight gain NNH=6; QTP sedation/somnolence NNH=5)." | 4.90 | Balancing benefits and harms of treatments for acute bipolar depression. ( Calabrese, JR; Citrome, L; Dell'Osso, B; Frye, MA; Ketter, TA; Miller, S, 2014) |
| "Olanzapine/fluoxetine (Symbyax) is an oral once-daily fixed-dose combination of the atypical antipsychotic olanzapine and the selective serotonin reuptake inhibitor (SSRI) fluoxetine that is approved in the US for the treatment of depressive episodes associated with bipolar disorder in adults." | 4.84 | Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression. ( Deeks, ED; Keating, GM, 2008) |
| "Fluoxetine use was not associated with an increased risk of acute pancreatitis compared with citalopram or other SSRIs." | 4.12 | Investigation of the potential association between the use of fluoxetine and occurrence of acute pancreatitis: a Danish register-based cohort study. ( Aakjær, M; Andersen, M; Dalhoff, KP; De Bruin, ML; Kristiansen, SB; Pape, K; Sessa, M, 2022) |
| " The purpose of our study was to determine if antidepressants improve depression via the NO pathway using an acute depressive rat model induced by L-arginine (AR)." | 3.81 | Antidepressant action via the nitric oxide system: A pilot study in an acute depressive model induced by arginin. ( Abe, M; Mori, Y; Nakata, S; Ochi, S; Ueno, S; Yamazaki, K; Yoshino, Y, 2015) |
| "Myocarditis is an increasingly recognized complication associated with the use of clozapine." | 3.74 | Acute myocarditis associated with clozapine. ( Howpage, P; Varambally, S, 2007) |
| " We present the case of a young man who developed an acute akathisia and dystonia after inadvertent overdose of olanzapine (Zyprexa) in the setting of a recent discontinuation of fluoxetine." | 3.73 | Acute olanzapine-induced akathisia and dystonia in a patient discontinued from fluoxetine. ( Dufel, S; Paige, T; Vena, J, 2006) |
| "We report a case of a 32-year-old woman who developed paroxysmal episodes of right hemidystonia 2 days after taking fluoxetine." | 3.71 | Acute paroxysmal dystonia induced by fluoxetine. ( Callejo, JM; Domínguez-Morán, JA; Fernández-Ruiz, LC; Martínez-Castrillo, JC, 2001) |
| "To prevent recurrence (i." | 2.82 | Quantifying and qualifying the preventive effects of acute-phase cognitive therapy: Pathways to personalizing care. ( Clark, LA; Jarrett, RB; Minhajuddin, A; Thase, ME; Vittengl, JR, 2016) |
| "Many patients with major depressive disorder (MDD) who achieve full remission after antidepressant treatment still have residual depressive symptoms." | 2.76 | Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. ( Baer, L; Clain, A; Iovieno, N; Nierenberg, AA; van Nieuwenhuizen, A, 2011) |
| "Patients (N = 284) with DSM-IV major depressive disorder were randomly assigned in a double-blind fashion to fluoxetine, paroxetine, or sertraline for 10 to 16 weeks of treatment." | 2.70 | Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. ( Fava, M; Gonzales, JS; Hoog, SL; Judge, RA; Kopp, JB; Nilsson, ME, 2002) |
| "The duration of the therapy of migraine between the attacks was 12 weeks." | 2.69 | [A comparative efficiency of amitriptyline, fluoxetine and maprotiline in prevention of migraine in attack-free period]. ( Amelin, AV; Gonchar, MA; Korenko, LA; Skoromets, AA; Tumelevich, BCh, 2000) |
| " A daily dosage of 300 mg of moclobemide and 20 mg of fluoxetine would thus appear to be comparable both in antidepressant efficacy and tolerability." | 2.67 | Moclobemide versus fluoxetine for major depressive episodes. ( Bruynooghe, F; De Cuyper, H; Demeulemeester, F; Geerts, S; Haazen, L, 1994) |
| "Fluoxetine was ingested alone in 87 cases and with ethanol or other drugs in the remaining 147 cases." | 2.67 | Acute fluoxetine overdose: a report of 234 cases. ( Borys, DJ; Day, LC; Krenzelok, EP; Ling, LJ; Reisdorf, JJ; Setzer, SC, 1992) |
| "Providing an accurate and timely bipolar depression diagnosis is critical for the proper treatment of the patient." | 2.50 | Acute and maintenance treatments for bipolar depression. ( Ketter, TA, 2014) |
| "Survival of lipopolysaccharide-induced endotoxic shock was improved in Tph1(-/-) mice." | 1.39 | Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. ( Bader, M; Bode, C; Brill, A; Carbo, C; Cicko, S; Cifuni, SM; Demers, M; Duerschmied, D; Herr, N; Idzko, M; Mauler, M; Suidan, GL; Wagner, DD, 2013) |
| " This was combined with two different doses of fluoxetine (10 and 20 mg/kg)." | 1.37 | Evaluation of antidepressant activity of ropinirole coadministered with fluoxetine in acute and chronic behavioral models of depression in rats. ( Ghorpade, S; Manjrekar, N; Sonawane, D; Tripathi, R, 2011) |
| "Treatment with fluoxetine during CRS reversed the decrease in DG H3K9me3, but had no effect on the other marks." | 1.35 | Regulation of hippocampal H3 histone methylation by acute and chronic stress. ( Hunter, RG; McCarthy, KJ; McEwen, BS; Milne, TA; Pfaff, DW, 2009) |
| " These children will have no adverse effects or only minimal effects and require no emergency treatment or gastric decontamination." | 1.32 | Fluoxetine exposures: are they safe for children? ( Baker, SD; Morgan, DL, 2004) |
| " A full pharmacokinetic time profile of lithium was obtained." | 1.31 | Bayesian pharmacokinetics of lithium after an acute self-intoxication and subsequent haemodialysis: a case report. ( Beijnen, JH; Kerbusch, T; Mathôt, RA; Meesters, EW; Otten, HM; Schellens, JH; van Kan, HJ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 26 (39.39) | 18.2507 |
| 2000's | 27 (40.91) | 29.6817 |
| 2010's | 11 (16.67) | 24.3611 |
| 2020's | 2 (3.03) | 2.80 |
| Authors | Studies |
|---|---|
| Aakjær, M | 1 |
| Kristiansen, SB | 1 |
| Pape, K | 1 |
| Sessa, M | 1 |
| Dalhoff, KP | 1 |
| De Bruin, ML | 1 |
| Andersen, M | 1 |
| Shiner, B | 1 |
| Leonard, CE | 1 |
| Gui, J | 1 |
| Cornelius, SL | 1 |
| Schnurr, PP | 1 |
| Hoyt, JE | 1 |
| Young-Xu, Y | 1 |
| Watts, BV | 1 |
| Ketter, TA | 3 |
| Vittengl, JR | 2 |
| Clark, LA | 2 |
| Thase, ME | 2 |
| Jarrett, RB | 2 |
| Gupta, D | 1 |
| Radhakrishnan, M | 1 |
| Kurhe, Y | 1 |
| Thangaraj, D | 1 |
| Prabhakar, V | 1 |
| Kanade, P | 1 |
| Miller, S | 1 |
| Dell'Osso, B | 1 |
| Calabrese, JR | 1 |
| Frye, MA | 1 |
| Citrome, L | 1 |
| Tyler, KL | 1 |
| Yoshino, Y | 1 |
| Ochi, S | 1 |
| Yamazaki, K | 1 |
| Nakata, S | 1 |
| Abe, M | 1 |
| Mori, Y | 1 |
| Ueno, S | 1 |
| Minhajuddin, A | 1 |
| Tao, R | 2 |
| Emslie, G | 1 |
| Mayes, T | 2 |
| Nakonezny, P | 1 |
| Kennard, B | 1 |
| Hughes, C | 1 |
| Nierenberg, AA | 2 |
| Hunter, RG | 1 |
| McCarthy, KJ | 1 |
| Milne, TA | 1 |
| Pfaff, DW | 1 |
| McEwen, BS | 1 |
| Chollet, F | 1 |
| Tardy, J | 1 |
| Albucher, JF | 1 |
| Thalamas, C | 1 |
| Berard, E | 1 |
| Lamy, C | 1 |
| Bejot, Y | 1 |
| Deltour, S | 1 |
| Jaillard, A | 1 |
| Niclot, P | 1 |
| Guillon, B | 1 |
| Moulin, T | 1 |
| Marque, P | 1 |
| Pariente, J | 1 |
| Arnaud, C | 1 |
| Loubinoux, I | 1 |
| Iovieno, N | 1 |
| van Nieuwenhuizen, A | 1 |
| Clain, A | 1 |
| Baer, L | 2 |
| Ghorpade, S | 1 |
| Tripathi, R | 1 |
| Sonawane, D | 1 |
| Manjrekar, N | 1 |
| Duerschmied, D | 1 |
| Suidan, GL | 1 |
| Demers, M | 1 |
| Herr, N | 1 |
| Carbo, C | 1 |
| Brill, A | 1 |
| Cifuni, SM | 1 |
| Mauler, M | 1 |
| Cicko, S | 1 |
| Bader, M | 1 |
| Idzko, M | 1 |
| Bode, C | 1 |
| Wagner, DD | 1 |
| Levkovitz, Y | 1 |
| Caftori, R | 1 |
| Avital, A | 1 |
| Richter-Levin, G | 1 |
| Kazlauskiene, D | 3 |
| Vainauskas, P | 3 |
| Kazlauskas, S | 1 |
| Rothschild, AJ | 1 |
| Duval, SE | 1 |
| Rakauskaite, D | 1 |
| Marksiene, R | 1 |
| Kiliuviene, G | 1 |
| Rocher, C | 1 |
| Spedding, M | 1 |
| Munoz, C | 1 |
| Jay, TM | 1 |
| Baker, SD | 1 |
| Morgan, DL | 1 |
| Orio, L | 1 |
| O'Shea, E | 1 |
| Sanchez, V | 1 |
| Pradillo, JM | 1 |
| Escobedo, I | 1 |
| Camarero, J | 1 |
| Moro, MA | 1 |
| Green, AR | 1 |
| Colado, MI | 1 |
| Iyengar, S | 1 |
| Webster, AA | 1 |
| Hemrick-Luecke, SK | 1 |
| Xu, JY | 1 |
| Simmons, RM | 1 |
| Trivedi, MH | 1 |
| Wan, GJ | 1 |
| Mallick, R | 1 |
| Chen, J | 1 |
| Casciano, R | 1 |
| Geissler, EC | 1 |
| Panish, JM | 1 |
| Gameiro, GH | 1 |
| Gameiro, PH | 1 |
| Andrade, Ada S | 1 |
| Pereira, LF | 1 |
| Arthuri, MT | 1 |
| Marcondes, FK | 1 |
| Veiga, MC | 1 |
| Vena, J | 1 |
| Dufel, S | 1 |
| Paige, T | 1 |
| Peterson, TJ | 1 |
| Feldman, G | 1 |
| Harley, R | 1 |
| Fresco, DM | 1 |
| Graves, L | 1 |
| Holmes, A | 1 |
| Bogdan, R | 1 |
| Papakostas, GI | 1 |
| Bohn, L | 1 |
| Lury, RA | 1 |
| Fava, M | 3 |
| Segal, ZV | 1 |
| Reznikov, LR | 1 |
| Grillo, CA | 1 |
| Piroli, GG | 1 |
| Pasumarthi, RK | 1 |
| Reagan, LP | 1 |
| Fadel, J | 1 |
| Varambally, S | 1 |
| Howpage, P | 1 |
| Candrian, M | 1 |
| Farabaugh, A | 1 |
| Pizzagalli, DA | 1 |
| Kennard, BD | 1 |
| Hughes, JL | 1 |
| Stewart, SM | 1 |
| Nightingale-Teresi, J | 1 |
| Carmody, T | 2 |
| Emslie, GJ | 2 |
| Deeks, ED | 1 |
| Keating, GM | 1 |
| Lonnqvist, J | 1 |
| Sihvo, S | 1 |
| Syvälahti, E | 1 |
| Sintonen, H | 1 |
| Kiviruusu, O | 1 |
| Pitkanen, H | 1 |
| Szabo, CP | 1 |
| Geerts, S | 1 |
| Bruynooghe, F | 1 |
| De Cuyper, H | 1 |
| Demeulemeester, F | 1 |
| Haazen, L | 1 |
| Katz, RJ | 1 |
| Rosenthal, M | 1 |
| Gatto, E | 1 |
| Pikielny, R | 1 |
| Micheli, F | 1 |
| Stokes, PE | 1 |
| Bobichon, R | 1 |
| Bernard, G | 1 |
| Mion, F | 1 |
| Vaamonde, J | 1 |
| del Real, MA | 1 |
| Ibáñez, R | 1 |
| Gudín, M | 1 |
| Lauterbach, EC | 1 |
| Shillcutt, SD | 1 |
| Detke, MJ | 1 |
| Johnson, J | 1 |
| Lucki, I | 1 |
| Zafar, HM | 1 |
| Paré, WP | 1 |
| Tejani-Butt, SM | 1 |
| Rush, AJ | 1 |
| Weinberg, WA | 1 |
| Kowatch, RA | 1 |
| Mayes, TL | 1 |
| Andrade, C | 1 |
| Cai, Q | 1 |
| Benson, MA | 1 |
| Talbot, TJ | 1 |
| Devadas, G | 1 |
| Swanson, HJ | 1 |
| Olson, JL | 1 |
| Kirchner, JP | 1 |
| Gambarana, C | 1 |
| Ghiglieri, O | 1 |
| Tolu, P | 1 |
| De Montis, MG | 1 |
| Giachetti, D | 1 |
| Bombardelli, E | 1 |
| Tagliamonte, A | 1 |
| Nielsen, AS | 1 |
| Mors, O | 1 |
| Michalak, A | 1 |
| Rose, C | 1 |
| Butterworth, RF | 1 |
| Amelin, AV | 1 |
| Skoromets, AA | 1 |
| Korenko, LA | 1 |
| Tumelevich, BCh | 1 |
| Gonchar, MA | 1 |
| Domínguez-Morán, JA | 1 |
| Callejo, JM | 1 |
| Fernández-Ruiz, LC | 1 |
| Martínez-Castrillo, JC | 1 |
| Hoog, SL | 1 |
| Judge, RA | 1 |
| Kopp, JB | 1 |
| Nilsson, ME | 1 |
| Gonzales, JS | 1 |
| Kerbusch, T | 1 |
| Mathôt, RA | 1 |
| Otten, HM | 1 |
| Meesters, EW | 1 |
| van Kan, HJ | 1 |
| Schellens, JH | 1 |
| Beijnen, JH | 1 |
| Río, J | 1 |
| Molins, A | 1 |
| Viguera, ML | 1 |
| Codina, A | 1 |
| Caley, CF | 1 |
| Friedman, JH | 1 |
| Black, B | 1 |
| Uhde, TW | 1 |
| Brewerton, TD | 1 |
| Shannon, M | 1 |
| Borys, DJ | 1 |
| Setzer, SC | 1 |
| Ling, LJ | 1 |
| Reisdorf, JJ | 1 |
| Day, LC | 1 |
| Krenzelok, EP | 1 |
| Flax, JW | 1 |
| Gray, J | 1 |
| Herbert, J | 1 |
| Vaz, FJ | 1 |
| Salcedo, MS | 1 |
| Mars, F | 1 |
| Dumas de la Roque, G | 1 |
| Goissen, P | 1 |
| Reccoppa, L | 1 |
| Welch, WA | 1 |
| Ware, MR | 1 |
| Browning, WN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Childhood Depression: Remission and Relapse[NCT00332787] | 200 participants | Interventional | 2000-06-30 | Completed | |||
| E-Rehabilitation: Aerobic Resistance Training for Stroke Survivors[NCT02938000] | 3 participants (Actual) | Interventional | 2016-08-31 | Completed | |||
| Pilot Study of Memantine for Enhanced Stroke Recovery[NCT02144584] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2014-01-31 | Active, not recruiting | ||
| FLOW Trial: Fluoxetine to Open the Critical Period Time Window to Improve Motor Recovery After Stroke[NCT03448159] | Phase 2 | 52 participants (Actual) | Interventional | 2019-01-01 | Completed | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Agomelatine in the Prevention of Poststroke Depression[NCT05426304] | Phase 4 | 420 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| Effects of 3 Months Daily Treatment With Selective Serotonin Reuptake Inhibitor (SSRI, Fluoxetine) on Motor Rehabilitation After Ischemic Stroke. FLAME Trial[NCT00657163] | Phase 2 | 100 participants (Anticipated) | Interventional | 2005-03-31 | Completed | ||
| Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463] | Phase 2 | 88 participants (Anticipated) | Interventional | 2021-07-18 | Recruiting | ||
| Effect of Serotonin and Levodopa Functional Recovery in Patients With Cerebral Infarction[NCT02386475] | Phase 4 | 39 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Efficacy Of Switching From SSRI to Desvenlafaxine on Cognitive Function In Patients With an Acute Episode of Major Depression[NCT03432221] | 36 participants (Anticipated) | Observational | 2018-04-03 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for fluoxetine and Acute Disease
| Article | Year |
|---|---|
Acute and maintenance treatments for bipolar depression.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depression; Dibenzothiazepin | 2014 |
Balancing benefits and harms of treatments for acute bipolar depression.
Topics: Acute Disease; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Diben | 2014 |
An analysis of the efficacy of treatments for bipolar depression.
Topics: Acute Disease; Adverse Drug Reaction Reporting Systems; Affect; Anticonvulsants; Antidepressive Agen | 2008 |
Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder.
Topics: Acute Disease; Affect; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agent | 2008 |
Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression.
Topics: Acute Disease; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Drug Combinations; Drug | 2008 |
A primary care perspective on management of acute and long-term depression.
Topics: Acute Disease; Adult; Aged; Depressive Disorder; Drug Administration Schedule; Drug Therapy, Combina | 1993 |
15 trials available for fluoxetine and Acute Disease
| Article | Year |
|---|---|
Stable remission and recovery after acute-phase cognitive therapy for recurrent major depressive disorder.
Topics: Acute Disease; Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depres | 2014 |
Quantifying and qualifying the preventive effects of acute-phase cognitive therapy: Pathways to personalizing care.
Topics: Acute Disease; Adult; Aged; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; | 2016 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Topics: Acute Disease; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Skill | 2011 |
Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse.
Topics: Acute Disease; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorde | 2011 |
The SSRIs drug Fluoxetine, but not the noradrenergic tricyclic drug Desipramine, improves memory performance during acute major depression.
Topics: Acute Disease; Adult; Analysis of Variance; Antidepressive Agents, Tricyclic; Depressive Disorder, M | 2002 |
How long should patients with psychotic depression stay on the antipsychotic medication?
Topics: Acute Disease; Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Clinical Protocols; Depr | 2003 |
Extreme response style in recurrent and chronically depressed patients: change with antidepressant administration and stability during continuation treatment.
Topics: Acute Disease; Adult; Chronic Disease; Cognitive Behavioral Therapy; Depressive Disorder, Major; Dos | 2007 |
Perceived stress and cognitive vulnerability mediate the effects of personality disorder comorbidity on treatment outcome in major depressive disorder: a path analysis study.
Topics: Acute Disease; Adolescent; Adult; Ambulatory Care; Cognition Disorders; Comorbidity; Depressive Diso | 2007 |
Maternal depressive symptoms in pediatric major depressive disorder: relationship to acute treatment outcome.
Topics: Acute Disease; Adolescent; Antidepressive Agents, Second-Generation; Child; Child of Impaired Parent | 2008 |
Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression.
Topics: Acute Disease; Adult; Antidepressive Agents; Benzamides; Depressive Disorder; Dose-Response Relation | 1995 |
Moclobemide versus fluoxetine for major depressive episodes.
Topics: Acute Disease; Adolescent; Adult; Aged; Antidepressive Agents; Benzamides; Depressive Disorder; Doub | 1994 |
Fluoxetine in child and adolescent depression: acute and maintenance treatment.
Topics: Acute Disease; Adolescent; Antidepressive Agents, Second-Generation; Anxiety; Chi-Square Distributio | 1998 |
[A comparative efficiency of amitriptyline, fluoxetine and maprotiline in prevention of migraine in attack-free period].
Topics: Acute Disease; Adrenergic Uptake Inhibitors; Adult; Amitriptyline; Analgesics, Non-Narcotic; Female; | 2000 |
Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia.
Topics: Acute Disease; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Depressive Disorder, | 2002 |
Acute fluoxetine overdose: a report of 234 cases.
Topics: Acute Disease; Adolescent; Adult; Child; Female; Fluoxetine; Humans; Male; Middle Aged; Poisoning; P | 1992 |
45 other studies available for fluoxetine and Acute Disease
| Article | Year |
|---|---|
Investigation of the potential association between the use of fluoxetine and occurrence of acute pancreatitis: a Danish register-based cohort study.
Topics: Acute Disease; Citalopram; Cohort Studies; Denmark; Fluoxetine; Humans; Pancreatitis; Selective Sero | 2022 |
Comparing Medications for DSM-5 PTSD in Routine VA Practice.
Topics: Acute Disease; Adult; Carbonic Anhydrase Inhibitors; Female; Fluoxetine; Humans; Male; Medication Ad | 2020 |
Antidepressant-like effects of a novel 5-HT3 receptor antagonist 6z in acute and chronic murine models of depression.
Topics: Acute Disease; Animals; Antidepressive Agents; Antioxidants; Behavior, Animal; Benzothiazoles; Bioma | 2014 |
Rationale for the evaluation of fluoxetine in the treatment of enterovirus D68-associated acute flaccid myelitis.
Topics: Acute Disease; Adolescent; Adult; Antiviral Agents; Child; Drug Discovery; Enterovirus D, Human; Flu | 2015 |
Antidepressant action via the nitric oxide system: A pilot study in an acute depressive model induced by arginin.
Topics: Acute Disease; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Arginine; Cyclopropanes | 2015 |
Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorder.
Topics: Acute Disease; Adolescent; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Maj | 2009 |
Regulation of hippocampal H3 histone methylation by acute and chronic stress.
Topics: Acute Disease; Animals; Chronic Disease; Dentate Gyrus; Fluoxetine; Hippocampus; Histones; Lysine; M | 2009 |
Evaluation of antidepressant activity of ropinirole coadministered with fluoxetine in acute and chronic behavioral models of depression in rats.
Topics: Acute Disease; Administration, Oral; Analysis of Variance; Animals; Antidepressive Agents; Behavior, | 2011 |
Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice.
Topics: Acute Disease; Animals; Blood Platelets; Chemotaxis; Endothelium, Vascular; Flow Cytometry; Fluoxeti | 2013 |
[Analysis of psychotropic drug mixtures using high-pressure liquid chromatography in acute poisoning cases].
Topics: Acute Disease; Amitriptyline; Analgesics, Opioid; Antidepressive Agents, Second-Generation; Antidepr | 2002 |
[Identification of the drugs in the mixture using thin-layer chromatography in sudden poisoning cases].
Topics: Acute Disease; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricy | 2003 |
[UV spectrophotometric research of drug mixture in sudden poisoning cases].
Topics: Acute Disease; Amitriptyline; Codeine; Data Interpretation, Statistical; Fluoxetine; Humans; Poisoni | 2003 |
Acute stress-induced changes in hippocampal/prefrontal circuits in rats: effects of antidepressants.
Topics: Acute Disease; Animals; Fluoxetine; Hippocampus; Injections, Intraperitoneal; Long-Term Potentiation | 2004 |
Fluoxetine exposures: are they safe for children?
Topics: Acute Disease; Age Distribution; Child Welfare; Child, Preschool; Coma; Diarrhea; Dose-Response Rela | 2004 |
3,4-Methylenedioxymethamphetamine increases interleukin-1beta levels and activates microglia in rat brain: studies on the relationship with acute hyperthermia and 5-HT depletion.
Topics: Acute Disease; Animals; Astrocytes; Binding, Competitive; Body Temperature; Brain; Cerebral Cortex; | 2004 |
Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.
Topics: Acute Disease; Amines; Amitriptyline; Animals; Conscious Sedation; Cyclohexanecarboxylic Acids; Cycl | 2004 |
Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
Topics: Activities of Daily Living; Acute Disease; Ambulatory Care; Cost-Benefit Analysis; Cyclohexanols; De | 2004 |
Nociception- and anxiety-like behavior in rats submitted to different periods of restraint stress.
Topics: Acute Disease; Adrenocorticotropic Hormone; Analgesics, Opioid; Animals; Anxiety; Chronic Disease; C | 2006 |
Acute olanzapine-induced akathisia and dystonia in a patient discontinued from fluoxetine.
Topics: Accidents; Acute Disease; Adult; Akathisia, Drug-Induced; Benzodiazepines; Drug Overdose; Dystonia; | 2006 |
Acute stress-mediated increases in extracellular glutamate levels in the rat amygdala: differential effects of antidepressant treatment.
Topics: Acute Disease; Amygdala; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; A | 2007 |
Acute myocarditis associated with clozapine.
Topics: Acute Disease; Adult; Antidepressive Agents; Antipsychotic Agents; Clozapine; Drug Interactions; Dru | 2007 |
Fluoxetine and sumatriptan: possibly a counterproductive combination.
Topics: Acute Disease; Adult; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Female; Flu | 1995 |
Adverse interaction of cyproheptadine with serotonergic antidepressants.
Topics: Acute Disease; Cyproheptadine; Depressive Disorder; Drug Interactions; Female; Fluoxetine; Humans; M | 1994 |
Fluoxetine in Tourette's syndrome.
Topics: Acute Disease; Adult; Fluoxetine; Humans; Male; Nail Biting; Obsessive-Compulsive Disorder; Severity | 1994 |
[Acute hepatitis during treatment with fluoxetine].
Topics: Acute Disease; Chemical and Drug Induced Liver Injury; Depressive Disorder; Female; Fluoxetine; Huma | 1993 |
[Acute dystonia induced by fluoxetine].
Topics: Acute Disease; Adult; Antidepressive Agents; Depressive Disorder; Dystonia; Female; Fluoxetine; Huma | 1996 |
Dyskinesia with fluoxetine: tardive or late-onset persistent, acute norfluoxetine dyskinesia?
Topics: Acute Disease; Animals; Diagnosis, Differential; Dyskinesia, Drug-Induced; Fluoxetine; Humans; Movem | 1997 |
Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression.
Topics: Acute Disease; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepress | 1997 |
Effect of acute or repeated stress on behavior and brain norepinephrine system in Wistar-Kyoto (WKY) rats.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Autoradiography; Behavior, Animal; Chronic Dise | 1997 |
Risperidone may worsen fluoxetine-treated OCD.
Topics: Acute Disease; Adult; Antipsychotic Agents; Drug Administration Schedule; Drug Interactions; Drug Th | 1998 |
Acute hepatitis due to fluoxetine therapy.
Topics: Acute Disease; Adult; Alanine Transaminase; Antidepressive Agents, Second-Generation; Aspartate Amin | 1999 |
Efficacy of an Hypericum perforatum (St. John's wort) extract in preventing and reverting a condition of escape deficit in rats.
Topics: Acute Disease; Animals; Appetite; Benzazepines; Chronic Disease; Disease Models, Animal; Electroshoc | 1999 |
Choreiform dyskinesia with acute onset and protracted course following fluoxetine treatment.
Topics: Acute Disease; Chorea; Depressive Disorder; Dyskinesia, Drug-Induced; Female; Fluoxetine; Humans; Mi | 1999 |
Loss of noradrenaline transporter sites in frontal cortex of rats with acute (ischemic) liver failure.
Topics: Acute Disease; Ammonia; Animals; Brain Edema; Carrier Proteins; Fluoxetine; Frontal Lobe; Hepatic En | 2001 |
Acute paroxysmal dystonia induced by fluoxetine.
Topics: Acute Disease; Adult; Depression; Dystonia; Female; Fluoxetine; Humans | 2001 |
Bayesian pharmacokinetics of lithium after an acute self-intoxication and subsequent haemodialysis: a case report.
Topics: Acute Disease; Acute Kidney Injury; Adult; Antimanic Agents; Antipsychotic Agents; Bayes Theorem; Bi | 2002 |
[Acute dystonia caused by fluoxetine].
Topics: Acute Disease; Dystonia; Female; Fluoxetine; Humans; Middle Aged | 1992 |
Does fluoxetine exacerbate Parkinson's disease?
Topics: Acute Disease; Adult; Aged; Ambulatory Care; Depressive Disorder; Female; Fluoxetine; Humans; Male; | 1992 |
Acute dystonia and fluoxetine.
Topics: Acute Disease; Adult; Depressive Disorder; Dystonia; Fluoxetine; Humans; Male | 1992 |
Possible clozapine exacerbation of bulimia nervosa.
Topics: Acute Disease; Adult; Bulimia; Clozapine; Dyskinesia, Drug-Induced; Female; Fluoxetine; Humans; Recu | 1992 |
Effect of fluoxetine on patients with multiple sclerosis.
Topics: Acute Disease; Depressive Disorder; Fluoxetine; Humans; Multiple Sclerosis | 1991 |
Fluoxetine treatment of depressive symptoms in acute intermittent porphyria.
Topics: Acute Disease; Adult; Depression; Female; Fluoxetine; Humans; Porphyrias | 1991 |
[Acute hepatitis during treatment with fluoxetine].
Topics: Acute Disease; Adult; Chemical and Drug Induced Liver Injury; Depression; Female; Fluoxetine; Humans | 1991 |
Acute dystonia and fluoxetine.
Topics: Acute Disease; Adult; Basal Ganglia Diseases; Depressive Disorder; Dystonia; Female; Fluoxetine; Hum | 1990 |
Exacerbation of symptoms of multiple sclerosis in a patient taking fluoxetine.
Topics: Acute Disease; Adult; Depressive Disorder; Female; Fluoxetine; Humans; Multiple Sclerosis | 1990 |